Amgen Gets Mixed Ruling In Patent Fight
A recombinant version of the kidney hormone erythropoietin (EPO), Epogen is used to increase red blood cells in patients with kidney failure and in for patients on dialysis. Its sales were $613 million for the second quarter of 2006.
The case stretches back to April 1997, when Amgen sought declaratory judgment against...
To view the full article, register now.